RT Journal Article
SR Electronic
T1 SUCCESSFUL MANUFACTURING OF CLINICAL-GRADE SARS-CoV-2 SPECIFIC T CELLS FOR ADOPTIVE CELL THERAPY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20077487
DO 10.1101/2020.04.24.20077487
A1 Wing Leung
A1 Teck Guan Soh
A1 Yeh Ching Linn
A1 Jenny Guek-Hong Low
A1 Jiashen Loh
A1 Marieta Chan
A1 Wee Joo Chng
A1 Liang Piu Koh
A1 Michelle Li-Mei Poon
A1 King Pan Ng
A1 Chik Hong Kuick
A1 Thuan Tong Tan
A1 Lip Kun Tan
A1 Michaela Su-fern Seng
YR 2020
UL http://medrxiv.org/content/early/2020/04/30/2020.04.24.20077487.abstract
AB Background Adoptive therapy with SARS-CoV-2 specific T cells for COVID-19 has not been reported. The feasibility of rapid clinical-grade manufacturing of virus-specific T cells from convalescent donors has not been demonstrated for this or prior pandemics.Methods One unit of whole blood was collected from each convalescent donor following standard blood bank practices. After the plasma was separated and stored separately, the leukocytes were stimulated using overlapping peptides of SARS-CoV-2, covering the immunodominant sequence domains of the S protein and the complete sequence of the N and M proteins. Thereaftesr, functionally reactive cells were enriched overnight using an automated device capturing IFNγ-secreting cells.Findings From 1×109 leukocytes, 0.56 to 1.16×106 IFNγ+ T cells were produced from each of the first two donors. Most of the T cells (64% to 71%) were IFNγ+, with preferential enrichment of CD56+ T cells, effector memory T cells, and effector memory RA+ T cells. TCRVβ spectratyping revealed oligoclonal distribution, with over-representation of subfamilies including Vβ3, Vβ16 and Vβ17. With just two donors, the probability that a recipient in the same ethnic group would share at least one donor HLA allele or one haplotype could be as high as >90% and >30%, respectively.Interpretations This study is limited by small number of donors and absence of recipient data; however, crucial first proof-of-principle data are provided demonstrating the feasibility of clinical-grade production of SARS-CoV-2 specific T cells for urgent clinical use, conceivably with plasma therapy concurrently. Our data showing that virus-specific T cells can be detected easily after brief stimulation with SARS-CoV-2 specific peptides suggest that a parallel diagnostic assay can be developed alongside serology testing.Funding The study was funded by a SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research Grant.Competing Interest StatementWL is a part-time advisor to Miltenyi Biomedicine.Clinical TrialNCT04351659Funding StatementThe study was funded by a SingHealth Duke-NUS Academic Medicine COVID-19 Rapid Response Research Grant. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.